Subscribe
Sign in
Home
Archive
Leaderboard
About
Trump's announcement shifts competition in the GLP-1 market
Who will benefit, and who won’t?
Nov 11
•
Ashwin Sharma, MD
15
1
3
Latest
Top
Discussions
Why Can't Anyone Stop Compounded GLP-1s?
Because federal, legal, and private forces won't allow it
Nov 2
•
Ashwin Sharma, MD
24
3
6
What Comes After the GLP-1 Hype?
It's messy, unglamorous stuff involving patients and insurers and crystal balls for pharma
Sep 28
•
Ashwin Sharma, MD
20
5
3
When GLP-1s become brain drugs
Doors are opening for Alzheimer's patients, for Novo, and for... Regeneron?
Sep 14
•
Ashwin Sharma, MD
28
3
3
Why Novo Nordisk and Eli Lilly Won't Compete on Price
But they will compete on market access and launch success
Sep 1
•
Ashwin Sharma, MD
20
5
5
The $100 Billion Overreaction
how do oral GLP-1s expand the market?
Aug 24
•
Ashwin Sharma, MD
17
4
Why Britain’s GLP-1 Patients Are Paying for America’s Drug Politics
1.5 million become collateral damage
Aug 17
•
Ashwin Sharma, MD
12
3
1
Why Novo Nordisk is Out of Options (Except One)
patents become weapons
Aug 5
•
Ashwin Sharma, MD
37
23
7
See all
GLP-1 Digest
The GLP-1 newsletter for founders, operators and investors.
Subscribe
Recommendations
In-Network
David Ohta
The Gut Group
Dr Arif Hussenbux MBBS
Big Pharma Sharma
Big Pharma Sharma
The Argument
Jerusalem Demsas
GLP-1 Digest
Subscribe
About
Archive
Recommendations
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
